Ab Science Stock Quote 0Q77 - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

3.835

Bid

3.74

Ask

3.93

Volume

4,446

0.00 Day's Range 0.00

3.835 52 Week Range 3.835

Market Cap

57.32M

Previous Close

3.835

Open

Last Trade

1.25

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

2,532

Shares Outstanding

46,602,000

Dividend Yield

PE Ratio

-4.78

Earnings Per Share (EPS)

-0.26

Revenue

970k

Net Profit

-11.99M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.ab-science.com

Headquarters

Paris, Paris, Fra

Founded

1970

Ab Science Sa is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0Q77. The last closing price for Ab Science was 3.84 €. Over the last year, Ab Science shares have traded in a share price range of 3.835 € to 3.835 €.

Ab Science currently has 46,602,000 shares outstanding. The market capitalization of Ab Science is 57.32 € million. Ab Science has a price to earnings ratio (PE ratio) of -4.78.

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS PRESS RELEASE...

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE...

AB Science communique un rectificatif sur les comptes consolidés au 31 décembre 2023

AB Science communique un rectificatif sur les comptes consolidés au 31 décembre 2023 COMMUNIQUE RECTIFICATIF COMMUNIQUE RECTIFICATIF SUR LES COMPTES CONSOLIDES AU 31 DECEMBRE 2023...

AB Science reports its revenues for the year 2023 and provides an update on its activities

AB Science reports its revenues for the year 2023 and provides an update on its activities PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE...

AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036

AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036 COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE...

AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient

AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment...

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science PRESS RELEASE THE...

AB Science announces a slight delay in the publication of its 2023 annual financial report

AB Science announces a slight delay in the publication of its 2023 annual financial report PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL...

AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune

AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune COMMUNIQUÉ DE PRESSE DE NOUVELLES...

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	3.835	3.835	3.835	502	3.835	DE
4	3.835	3.835	3.835	850	3.835	DE
12	3.835	3.835	3.835	2532	3.835	DE
26	3.835	3.835	3.835	3504	3.835	DE
52	3.835	3.835	3.835	8623	3.835	DE
156	3.835	3.835	3.835	5566	3.835	DE
260	3.835	3.835	3.835	5564	3.835	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GRDIGRIID Infrastructure Inc	$ 1.11 (98.21%)	155.65M
ZAPPZapp Electric Vehicles Group Ltd	$ 2.33 (71.32%)	91.49M
MGOLMGO Global Inc	$ 0.725 (58.16%)	160.27M
RELIReliance Global Group Inc	$ 0.61 (55.97%)	139.38M
HAOHaoxi Health Technology Ltd	$ 6.36 (38.26%)	693.26k
WHLRWheeler Real Estate Investment Trust Inc	$ 2.75 (-82.51%)	164.01k
KAVLKaival Brands Innovations Group Inc	$ 2.90 (-35.56%)	1.31M
MBIOMustang Bio Inc	$ 0.5605 (-34.07%)	38.18M
SONNSonnet BioTherapeutics Holdings Inc	$ 1.04 (-32.03%)	432.19k
NKLANikola Corporation	$ 0.3279 (-31.82%)	269.83M
NVDANVIDIA Corporation	$ 130.78 (-3.54%)	518.09M
NKLANikola Corporation	$ 0.3279 (-31.82%)	269.83M
SMXSMX Security Matters Public Company	$ 0.16 (34.45%)	177.78M
SQQQProShares UltraPro Short QQQ	$ 8.32 (2.46%)	166.97M
MGOLMGO Global Inc	$ 0.725 (58.16%)	160.27M